PEAR Therapeutics to Collaborate with Novartis to Develop Prescription Digital Therapeutics
PEAR Therapeutics announced today that it has entered into a collaboration with Novartis to develop novel prescription digital therapeutics for schizophrenia and multiple sclerosis (MS). These [...]
Magellan Health Continues Innovation and Efforts to Improve Outcomes for Patients with Substance Use Disorder
Magellan Health, Inc. (NASDAQ: MGLN) has long been the national leader in the use of digital innovation to help those struggling with various medical and behavioral conditions, including [...]
PEAR Therapeutics Completes $50 Million Series B Financing
PEAR Therapeutics, the leader in prescription digital therapeutics, today announced that it has successfully closed a $50 million Series B financing led by Temasek. Link
Digital Medicine Changemaker Pear Therapeutics to Receive CNS Summit 2017 Innovation Award
CNS Summit, a community at the intersection of life sciences and technology, will bring together key figures leading the digital transformation of the life science industry. Link
Pear Therapeutics Receives EAP Designation from FDA for reSET-O™ Prescription Digital Therapeutic to Treat Opioid Use Disorder
Pear Therapeutics, the leader in prescription digital therapeutics, today announced that it has received an Expedited Access Pathway (EAP) designation from the U.S. Food and Drug Administration [...]
Pear Therapeutics Obtains FDA Clearance of the First Prescription Digital Therapeutic to Treat Disease
Pear Therapeutics, the leader in a new era of prescription digital therapeutics, today announced that the U.S. Food and Drug Administration (FDA) has granted Pear’s De Novo request, [...]
Digital Addiction Therapy Could Be First FDA-Approved App
Digital therapy could soon be prescribed and reimbursed like a pharmaceutical drug for patients with chronic substance use disorder. “This could be a watershed moment for digital [...]
